(Total Views: 333)
Posted On: 10/02/2017 7:50:02 PM
Post# of 72446
BP's interest in the Big Three
"We had said that confidential disclosure agreements have been signed with several pharmas interested in our drug candidates; to some, they're interested in one compound. Others have requested information on a combination of Brilacidin and Kevetrin and Prurisol."
B-UP
"We've actively engaged with multiple large pharmas, who have expressed an interest in Brilacidin inflammatory bowel disease. The pharma industry is quite interested in pursuing novel IBD therapies one of the more active therapeutic areas when it comes to dealmaking."
https://seekingalpha.com/article/4080068-inno...art=single
Prurisol
"We have entered into multiple non-disclosure agreements with large pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the trial results support such a relationship."
https://www.sec.gov/Archives/edgar/data/13552...ix_10k.htm
Kevetrin
"What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,"
http://www.ipharminc.com/press-release/2017/9...er-trial-1
"We had said that confidential disclosure agreements have been signed with several pharmas interested in our drug candidates; to some, they're interested in one compound. Others have requested information on a combination of Brilacidin and Kevetrin and Prurisol."
B-UP
"We've actively engaged with multiple large pharmas, who have expressed an interest in Brilacidin inflammatory bowel disease. The pharma industry is quite interested in pursuing novel IBD therapies one of the more active therapeutic areas when it comes to dealmaking."
https://seekingalpha.com/article/4080068-inno...art=single
Prurisol
"We have entered into multiple non-disclosure agreements with large pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the trial results support such a relationship."
https://www.sec.gov/Archives/edgar/data/13552...ix_10k.htm
Kevetrin
"What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,"
http://www.ipharminc.com/press-release/2017/9...er-trial-1
(6)
(0)
